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Background. Natural infection induces partial immunity to Chlamydia trachomatis. Identification of chlamydial antigens that
induce interferon γ (IFN-) secretion by T cells from immune women could advance vaccine development.
Methods. IFN-γ production by CD4+ and CD8+ peripheral blood T cells from 58 high-risk women was measured after coculture
with antigen-presenting cells preincubated with recombinant Escherichia coli expressing a panel of 275 chlamydial antigens. Quantile
median regression analysis was used to compare frequencies of IFN-γ responses in women with only cervical infection to those in
women with endometrial infection and frequencies in women who remained uninfected for over 1 year to those in women who
developed incident infection. Statistical methods were then used to identify proteins associated with protection.
Results. A higher median frequency of CD8+ T-cell responses was detected in women with lower genital tract chlamydial in-
fection, compared with those with upper genital tract chlamydial infection (13.8% vs 9.5%; P = .04), but the CD4+ T-cell response
frequencies were not different. Women who remained uninfected displayed a greater frequency of positive CD4+ T-cell responses
(29% vs 18%; P < .0001), compared with women who had incident infection, while the frequencies of CD8+ T-cell responses did not
differ. A subset of proteins involved in central metabolism, type III secretion, and protein synthesis were associated with protection.
Conclusions. Investigations in naturally exposed women reveal protective responses and identify chlamydial vaccine candidate
antigens.
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Chlamydia trachomatis causes the world’s most prevalent bacte-
rial sexually transmitted infection, with approximately 3.0 mil-
lion new infections in the United States [1] and 90 million new
infections globally each year [2]. Adolescents and young adults
are at greatest risk for infection [3]. Despite accurate diagnostic
tests and effective antibiotic therapies, it remains an important
global health problem. Most infections are asymptomatic, lead-
ing to undetected and untreated infections and sustained high
prevalence. Although only a small proportion of infected
women develop severe morbidities, including chronic pelvic
pain, ectopic pregnancy, and tubal factor infertility, their abso-
lute number is great because infection prevalence is high, driv-
ing annual healthcare costs in the United States to an estimated
$517 million [4]. Although antibiotics clear infection,
destructive pathology is not ameliorated. Thus, a vaccine is
urgently needed.
Evidence for naturally acquired immunity to chlamydia in
humans is accumulating, including a documented decreased
prevalence with increasing age despite continued exposure
[5], decreased infection concordance between sex partners
with increasing age of the partners, and lower bacterial loads
among individuals with a history of infection [6]. Furthermore,
in a prospective study of 200 women, those whose chlamydial
infections cleared spontaneously between testing and treatment
were less likely to become reinfected during the follow-up peri-
od [7]. Human vaccine data are derived solely from trials of live
and inactivated whole-cell vaccines administered to children
living in trachoma-endemic areas in the 1960s, when short-
term and serovar-specific protection against reinfection was ob-
served [8–10]. Animal models have illuminated the importance
of T cells in control of infection [11]. Resolution of infection
with attenuated chlamydial strains leads to partial immunity
from reinfection and to significant protection from disease in
mice [12] and nonhuman primates [13]. Data from the mouse
model indicate that IFN-γ–producing CD4+ T-helper type 1
cells play a central role in infection clearance [14–16], while
antichlamydia antibody contributes to resistance to reinfection
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[17]. Although CD8+ T cells are dispensable for immunity in
the mouse genital tract model [18], a role for CD8+ T cells in
vaccine-induced protection from ocular infection was demon-
strated in macaques [19] and C. trachomatis–specific human
CD8+ T-cell clones inhibit chlamydial replication [20], indicat-
ing a need to further explore their contribution to protection.
In this study, we build on previous investigations [21, 22] by
determining the relative contribution of IFN-γ–producing
CD4+ and CD8+ T cells to the control of infection and to pro-
tection against incident infection in highly exposed women
[23]. We selected a panel of 275 chlamydial proteins to probe
antigen-specific CD4+ and CD8+ T-cell IFN-γ responses in
women whose extent of infection was defined at enrollment
and who were followed longitudinally for reinfection. We hy-
pothesized that women who had infection limited to the cervix
would exhibit a greater frequency of positive responses to a spe-
cific subset of proteins as compared to women in whom infec-
tion ascended to their upper genital tract. Additionally, we
hypothesized that women who remained uninfected over 1
year would recognize a specific subset of antigens with in-
creased frequency, compared with women who developed inci-
dent infection. Our overall goal was to use a minimally biased
screening assay to probe peripheral blood samples available
from women with evidence of natural immune protection to
identify candidate vaccine T-cell antigens and thereby advance
vaccine development.
METHODS
Patient Populations
Blood from 97 women recruited into a previously described T-
Cell Response Against Chlamydia (TRAC) cohort was pro-
cessed for analysis by a T-cell IFN-γ assay [23]. The institutional
review boards for human research of the University of Pitts-
burgh and the University of North Carolina approved the
study protocol. All participants provided written informed con-
sent at the time of enrollment and agreed to be contacted to re-
turn for follow-up visits 1, 4, 8, and 12 months after enrollment.
TRAC was a longitudinal cohort study investigating cellular
responses important for protection against incident C. tracho-
matis genital tract infection. A total of 225 women aged 15–
35 years with lower genital tract sexually transmitted infection
(STI) or who were at risk for STI were enrolled in the study from
3 urban sites in Pittsburgh, Pennsylvania, during 2011–2015.
Eligibility criteria included clinical evidence of mucopurulent
cervicitis, diagnosis of chlamydial infection prior to treatment,
or reported sexual contact with an individual with a recent di-
agnosis of chlamydial urethritis or nongonococcal urethritis.
Women with a diagnosis of pelvic inflammatory disease
(PID), according to the Centers for Disease Control and Preven-
tion guidelines [24], were excluded from this study and offered
enrollment in a parallel study comparing PID antibiotic
regimens.
At enrollment, study personnel obtained demographic data
and a standardized medical history. Each participant completed
a questionnaire, and cervical and endometrial swab samples
were obtained for microbiologic testing [23]. Peripheral blood
mononuclear cells (PBMCs) were obtained for T-cell assays.
Participants returned for cervical infection screening and
PBMC collection 1, 4, 8, and 12 months after enrollment. A
standardized questionnaire was administered at each follow-
up visit, addressing the participant′s interim medical and sexual
history. PBMCs available from the first 97 women enrolled in
the cohort were processed for assay; assay failure occurred for
39 women, owing to poor cell viability or inadequate cell num-
bers after expansion, leaving findings from 58 women for com-
parative analysis.
Definition of Clinical and Microbiological Subgroups
Women were assigned to groups according to the extent of their
infection at enrollment. Women with a cervical swab positive
for chlamydia by nucleic acid amplification testing (NAAT)
but with a negative chlamydia NAAT result for the endometrial
sample were defined as Cervix+. Women who tested positive for
chlamydia at the cervix and in the endometrium were defined as
Endo+. Among 58 women analyzed, 16 (28%) were uninfected,
27 (47%) had lower genital tract infection (the Cervix+ group),
and 15 (26%) had upper genital tract infection (the Endo+
group). No participants tested positive solely in the endometri-
um. The chlamydial cervical burden was estimated via quanti-
tative NAAT, using genomic DNA extracted from reserved
cervical swab eluates as a template [23].
Women were also grouped on the basis of their infection sta-
tus throughout follow-up. The susceptible group contained
women who tested positive for chlamydial infection at any fol-
low-up visit or who reported having an infection between visits
that was diagnosed at an outside clinic. Women who tested neg-
ative at 4 study follow-up visits and never reported having an
infection between visits composed the follow-up–negative
group. Within these groups, 31 women (53%) were follow-up
negative, and 27 (47%) were susceptible.
Selection and Preparation of Antigen Panel
An initial ATLAS screen (see protocol details below) was con-
ducted on a group of 141 subjects by using the entire proteome
of C. trachomatis D/UW-3/Cx, which includes approximately
960 candidate chlamydial antigens [21]. Chlamydial proteins
were selected for inclusion in further assays if they elicited an
IFN-γ response in 15% of all individuals tested and were thus
considered immunogenic or if they induced a significantly
greater frequency of IFN-γ responses in persons who exhibited
an effective immune response versus persons with an ineffective
immune response and were thus potentially associated with
protection (Supplementary Table 1). An “effective” immune re-
sponse was defined as one that spontaneously resolved infection
or one that kept an individual uninfected despite sexual
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exposure to an infected person. An immune response was
deemed “ineffective” in women with acute chlamydial PID or
individuals with a diagnosis of chlamydia who did not clear
infection by the time they returned for treatment >2 weeks
later [21].
ATLAS T-Cell Screen
PBMCs were isolated from heparinized whole blood by density
gradient centrifugation and stored in liquid nitrogen. CD14+
monocytes, CD4+ T cells, and CD8+ T cells were isolated by
magnetic bead sorting [21]. Monocyte-derived dendritic cells
(MDDCs) were generated to serve as antigen-presenting cells
(APCs), while CD8+ and CD4+ T cells were nonspecifically ex-
panded with anti-CD3/CD28 Dynabeads (ThermoFisher) and
20 U/mL recombinant human interleukin 2 for 6 to 7 days.
The cells were rested for 48 hours with no cytokine, and the ex-
pansion beads were removed ≥4 hours before the cell-based
assay. MDDCs were added to the Escherichia coli expression
panel in duplicate at a target cell ratio of 1:100 MDDCs to bac-
teria. After 2 hours of incubation at 37°C, the MDDC-bacte-
rium layer was fixed with 0.1% paraformaldehyde and
washed; 4 × 104 T cells were added to each well of pulsed
MDDCs and cocultured for 24 hours. This method results in
antigen presentation within <2 hours [25]. Cell-free superna-
tants were harvested in duplicate and assayed via the OptEIA
human IFN-γ enzyme-linked immunosorbent assay (Becton
Dickinson, Franklin Lakes, NJ). Positive-control wells con-
tained T cells stimulated with phytohemagglutinin (PHA) at
5 μg/mL. Negative-control wells contained E. coli expressing
green fluorescent protein (GFP) [21]. Each candidate protein
was expressed in 2 separate E. coli strains for optimal antigen
presentation to CD4+ and CD8+ T cells.
Statistical Analysis
Four-parameter logistic curve fitting was used to calculate the
concentration of IFN-γ. A positive response to antigen was de-
fined as a mean IFN-γ response to antigen greater than the sum
of the mean response to GFP (+2 SDs). To compare T-cell re-
sponses in the Endo+ group to those in the Cervix+ group, as
well as T-cell responses in the susceptible group to those in the
follow-up–negative group, we used quantile (median) regres-
sion analyses. Quantile regression provides more-robust estima-
tions against response measurement outliers and unbiased
estimates even when equal variance assumptions are violated.
To determine specific proteins that were significantly more fre-
quently recognized in Cervix+ women, we used the Fisher exact
test of cross-sectional enrollment data. To identify specific pro-
teins associated with resistance to incident infection over time,
we used mixed-effects logistic regression for repeated measures.
The covariate “sex with a new partner since last visit” was ad-
justed in the model. All analyses were conducted using R (ver-
sion 3.1.1). Immunodominant proteins were defined as the 20
proteins that elicited the highest CD4+ or CD8+ T-cell response
frequencies among the 58 evaluable participants in the cohort.
For clinical and bacterial burden data, if outcomes were contin-
uous with a normal distribution, the Student t test was conduct-
ed; for ordinal or interval outcomes, the Wilcoxon signed ranks
test was used; and for categorical outcomes, the χ2 test was used
unless cell sizes were <5, in which case the Fisher exact test was
used. A P value of .05 was used to determine significance for all
comparisons except for identification of potentially important
protein antigens, for which we used a P value of .10.
RESULTS
Baseline Patient Characteristics
We processed PBMCs from 97 women from the TRAC cohort
for T-cell analyses; data for 58 who had evaluable T-cell re-
sponses are reported. Their sociodemographic characteristics
are similar to those previously reported for the entire cohort
(Supplementary Table 2) [23]. Follow-up rates were high,
with 74% attending all 4 visits, and 93% attending at least 3.
Sexual Exposure and Sexual Behavior in the Clinical Groups
STI exposure data were similar in women in the Cervix+ and
Endo+ groups (Supplementary Table 3). A comparison of sus-
ceptible and follow-up–negative women revealed no difference
in condom use frequency (approximately 50% of opportunities
for each group). Gonococcal infection during follow-up was as-
sociated with reinfection (P = .04, by the Fisher exact test). In
addition, 78% of susceptible women reported having a new
Figure 1. Comparison of cervical Chlamydia trachomatis burden between women
with lower genital tract (the Cervix+ group) and those with upper genital tract (the
Endo+ group) infection at enrollment. The lower, middle, and upper lines of the box
correspond to the 25th, 50th, and 75th percentiles, respectively, for each group. The
x-axis indicates the clinical groups, and the y-axis shows the log10 bacterial copies
per cervical swab eluate. Each dot represents 1 subject’s sample.
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sex partner during follow-up, compared with 29% of follow-up–
negative women (P = .0006, by the χ2 test).
CD4+ and CD8+ T-Cell Responses Among Women in the Endo+ and
Cervix+ Groups
Women in the Cervix+ group also had a lower mean cervical
bacterial burden when compared to women in the Endo+
group (P = .02, by the t test; Figure 1). This could indicate either
a shorter duration or superior control of infection. Evaluation of
questionnaires revealed that the median time between the most
recent sexual encounter and the diagnosis of infection did not
differ for women in the Cervix+ (9 days) and Endo+ (12 days)
groups (P = .16, by the Wilcoxon test). Thus, more-recent infec-
tion was insufficient to explain the lower cervical burden in the
Cervix+ group, which implied a possible role for the immune
response in limiting infection.
A comparison of median response frequencies for CD4+ T
cells revealed no difference between the Cervix+ and Endo+
groups (25% and 23.8%, respectively; P = .53; Figure 2A).
However, a higher median frequency of CD8+ T-cell responses
was detected in the Cervix+ group, compared with the Endo+
group (13.8% vs 9.5%; P = .04; Figure 2B). Examination of the
response frequencies to individual proteins revealed that
CD4+ T cells from women in the Cervix+ group recognized
5 proteins with a significantly higher frequency (P < .10),
compared with the Endo+ group (Figure 2C and Table 1),
and CD8+ T cells from the Cervix+ group recognized a subset
of 14 proteins with a higher frequency (P < .10) than those
from the Endo+ group (Figure 2D and Table 1). Three of
the antigens recognized by CD8+ T cells with increased fre-
quency (CT461, CT511, and CT529) were among the top 20
immunodominant proteins associated with CD8+ T cells in
Figure 2. Distribution of relative frequencies of positive CD4+ and CD8+ T-cell responses to a panel of chlamydial antigens, determined by ATLAS technology, among women
with lower genital tract (Cervix+) and upper genital tract (Endo+) infection at enrollment. A and B, Per protein distributions of positive CD4+ (A) and CD8+ (B) T-cell responses to
chlamydial proteins in the panel among women in the Cervix+ and Endo+ groups. The x-axis is the frequency of positive T-cell responses in the 2 groups of patients; the y-axis is
the smooth fit curve of the number of proteins among the 275 proteins examined that were recognized at a particular frequency. A, The median positive response frequency of
CD4+ T cells from the Cervix+ group was similar to that for the Endo+ group (25% and 23.8%, respectively; P = .53). B, CD8+ T cells from the Cervix+ group recognize a subset of
chlamydial proteins more frequently than those from the Endo+ group (median response frequency, 13.8% and 9.5%, respectively; P = .04). C and D, Plots of the relative
significance of the differential CD4+ (C) and CD8+ (D) T-cell responses to each protein in the panel among women in the Endo+ and Cervix+ groups. The x-axis represents
chlamydial proteins in the panel, and the y-axis is the inverse log10(P value), with the dashed horizontal lines representing P values of .10. C, CD4
+ T cells from women in the
Cervix+ group recognized 1 chlamydial protein significantly more frequently (P < .05) and 5 proteins more frequently (P < .10) than those in the Endo+ group. D, CD8+ T cells from
women in the Cervix+ group recognized 5 chlamydial proteins significantly more frequently (P < .05) and 14 proteins more frequently (P < .10) than those in the Endo+ group.
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the cohort, but none of the significant CD4+ T-cell–recog-
nized antigens were among the immunodominant proteins
associated with CD4+ T cells. These data suggest that specific
antigens drive host defense mechanisms in T cells during ac-
tive chlamydial infection to prevent ascension to the upper
genital tract.
CD4+ and CD8+ T-Cell Responses Among Follow-up–Negative and
Susceptible Women
We compared the response frequencies between follow-up–neg-
ative and susceptible women and found that follow-up–negative
women had a significantly greater median frequency of CD4+
T-cell responses (28.6%) as compared to susceptible women
(18%; P < .0001; Figure 3A). Examination of response frequen-
cies to individual proteins revealed that a subset of 37 proteins
were recognized by CD4+ T cells of follow-up–negative women
with a higher frequency (P < .10) (Figure 3C and Table 2) than
observed for susceptible women. In contrast to CD4+ T-cell re-
sponses, the median positive response rate of CD8+ T cells in
follow-up–negative and susceptible women did not differ
(8.7% and 12.5%, respectively; P = .07; Figure 3B), and no chla-
mydial proteins were recognized with increased frequency by
CD8+ T cells of follow-up–negative women (Figure 3D).
These data suggest that a specific subset of proteins recognized
by CD4+ T cells may reduce susceptibility to reinfection, and
these proteins should be further explored as vaccine candidates.
These proteins are summarized in Table 2. Four were among
the top 20 antigens recognized by CD4+ T cells from the entire
cohort: CT034, CT128, CT130, and CT368. No chlamydial pro-
teins were recognized with increased frequency by CD8+ T cells
from follow-up–negative women as compared to susceptible
women.
DISCUSSION
In this study, we identified specific antigens recognized by CD4+
and CD8+ T cells associated with protective immunity among a
high-risk cohort of women. Women in this cohort were highly
sexually active, with the majority reporting irregular use of con-
doms (93%) and prior C. trachomatis infection (66%). The high
rate of active infection (72%) and sampling of upper genital
tract tissue provided an opportunity to compare responses of
women in the Cervix+ and Endo+ groups.
Despite a lower mean antigen burden, T cells from women in
the Cervix+ group recognized chlamydial proteins with greater
(for CD8+ T cells; P = .04) or equivalent (for CD4+ T cells) fre-
quency as compared to women in the Endo+ group. Recogni-
tion of specific proteins by CD4+ and CD8+ T cells was
associated with improved control of infection. These findings
indicate an important role for antigen-specific T-cell responses
in preventing ascension of chlamydia to the upper genital tract.
This is significant, given that chronic disease sequelae in women
are primarily due to Fallopian tube scarring.
Table 1. Antigens Associated With Control of Lower Genital Tract Infection at Enrollment
Gene ID, by T-Cell Type Gene Antigen Response Frequency OR P Value
CD4+
CT564 yscT Type III secretion system protein YscT 0.132 . . .a .034
CT553 fmu RNA methyltransferase 0.245 4.84 .053
CT816 glmS Glucosamine-fructose-6-phosphate aminotransferase 0.189 7.59 .069
CT560 . . . Hypothetical protein 0.113 . . . .070
CT490 . . . Hypothetical protein 0.170 6.48 .071
CD8+
CT496.1 . . . Hypothetical protein 0.191 . . . .001
CT478 oppC_2 Oligopeptide ABC transporter permease 0.170 8.28 .034
CT725 birA Biotin synthetase 0.149 8.28 .034
CT529b . . . Hypothetical protein 0.234 5.33 .048
CT739 ftsK DNA translocase FtsK 0.255 5.33 .048
CT809 . . . Hypothetical protein 0.170 7.04 .064
CT814 . . . Hypothetical protein 0.170 7.04 .064
CT511Bb rl15 50S ribosomal protein L15 0.255 3.90 .064
CT536 dnaQ_2 DNA polymerase III subunit epsilon 0.087 . . . .066
CT574 pepP Aminopeptidase P 0.106 . . . .069
CT582B minD Chromosome partitioning ATPase 0.085 . . . .069
CT729 serS Serine-tRNA ligase 0.085 . . . .069
CT461b Metallophosphoesterase 0.191 3.97 .098
CT487 yhhF Methylase 0.170 3.97 .098
Abbreviations: ID, identifier; OR, odds ratio.
a The denominator is 0.
b Expresses an immunodominant protein.
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The high follow-up rate in our study provided the opportu-
nity to compare participants who subsequently acquired C. tra-
chomatis and those who remained uninfected over 12 months of
follow-up. We found that CD4+ T cells are the key players in
resistance to reinfection. Significantly greater CD4+ T-cell re-
sponse frequencies were detected in women who remained un-
infected, compared with susceptible women (P < .0001), and a
subset of 37 proteins were recognized more frequently by
CD4+ T cells from follow-up–negative women. Because having
sex with a new partner is a known risk factor and was associated
with acquisition (Supplementary Table 3), we adjusted for this
in our statistical analysis. Nevertheless, one third of follow-up–
negative women reported a new or multiple different partners
during follow-up. It is possible that some of the women that
we defined as follow-up negative were simply not exposed dur-
ing follow-up. However, the fact that higher rates of positive
CD4+ T-cell responses were coupled with enhanced responses
to a specific subset of proteins in follow-up–negative women
implies that these women were less susceptible because of either
increased past exposure or a more robust response to a single
past infection.
Our data suggest differing roles for CD8+ and CD4+ T cells in
response to chlamydial genital tract infection. CD8+ T cells may
contribute to limiting the bacterial burden and ascension of in-
fection, while CD4+ T cells appear to drive protection from re-
infection. In each case, limiting acute infection or preventing
repeat infection was dependent on having a T-cell response to
a specific subset of proteins, rather than on achieving a thresh-
old frequency of responses to random proteins. This points to-
ward certain proteins being better drivers of protective adaptive
responses. Notably, some of these antigens are among the most
frequently recognized proteins within the entire cohort.
Because the panel of proteins selected for evaluation was
based on criteria derived via our prior study [21], several pro-
teins reported in murine vaccine studies to induce protection
were not assessed. Immunization with native major outer
Figure 3. Distribution of relative frequencies of positive CD4+ and CD8+ T-cell responses to a panel of chlamydial antigens, determined by ATLAS technology, among
susceptible and follow-up–negative women, as defined by infection status during 1 year of follow-up. A and B, Per protein distributions of positive CD4+ (A) and CD8+ (B)
T-cell responses to chlamydial proteins in the panel among susceptible and follow-up–negative women. The x-axis is the frequency of positive T-cell responses in the 2 patient
groups; the y-axis is the smooth fit curve of the number of proteins among the 275 proteins examined that were recognized at a particular frequency. A, CD4+ T cells from follow-
up–negative women recognized a subset of chlamydial proteins more frequently than susceptible women (median response frequency, 28.6% and 18%, respectively; P < .0001).
B, The median positive response frequencies of CD8+ T cells were similar among follow-up–negative and susceptible women (8.7% and 12.5%, respectively; P = .07). C and D,
Plots of the relative significance of the differential CD4+ (C) and CD8+ (D) T-cell response to each protein in the panel among susceptible and follow-up–negative women. The x-
axis represents chlamydial proteins in the panel, and the y-axis is the inverse log10(P value), with the dashed horizontal line representing P = .10. C, CD4
+ T cells from follow-up–
negative women recognized 14 chlamydial proteins significantly more frequently (P < .05) and 37 proteins more frequently (P < .10) than those in susceptible women. D, No
proteins were recognized with increased frequency by CD8+ T cells from follow-up–negative women when compared to susceptible women.
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membrane protein (MOMP) protects against oviduct disease in
the murine model when delivered with adjuvant [26]. This pro-
tein was not included in our current screen because in the prior
screen it elicited a low frequency of T-cell responses [21], de-
spite MOMP immunoglobulin G (IgG) seropositivity in 40%
of the cohort (unpublished data). A prior study that examined
T-cell IFN-γ responses to 116 recombinant chlamydial antigens
in infected patients revealed responses to inner membrane and
cytoplasmic proteins only; MOMP was recognized only by IgG
[27]. These studies suggest that MOMP elicits poor T-cell re-
sponses in humans despite induction of antibody. Murine
studies reveal T-cell responses to MOMP [28], but differences
in cellular processing machinery in mice and humans at the
level of the proteasome and in major histocompatibility com-
plex lead to differences in antigen presentation [29]. Other pro-
teins that have induced protection in mouse vaccine models that
were not included in our screen included CPAF [30]; polymor-
phic membrane proteins E, F, and G [31, 32]; OmcB and rl16
[33]; and CT823 [34]. CrpA, IncA (an immunodominant,
inclusion membrane-associated protein), and PmpD were
examined in our panel, but response frequencies were not sig-
nificantly different among the subgroups. A hypothetical
Table 2. Antigens Associated With Protection From Chlamydia trachomatis Infection During 1 Year of Follow-up
Gene ID, by T Cell-Type Gene Antigen Response Frequency OR P Value
CD4+
CT308 atpA V-type ATP synthase subunit A 0.259 4.55 .018
CT020 lepB Signal peptidase I 0.291 4.41 .019
CT313 tal Transaldolase 0.327 3.54 .025
CT034a ytfF Cationic amino acid transporter 0.370 2.92 .032
CT156 . . . Hypothetical protein 0.255 4.08 .034
CT360 . . . Hypothetical protein 0.182 4.93 .035
CT134 . . . Hypothetical protein 0.259 3.31 .036
CT264 msbA ABC transporter ATP binding protein/permease 0.236 4.77 .039
CT421 . . . Hypothetical protein 0.283 2.97 .039
CT307 atpB V-type ATP synthase subunit B 0.273 3.20 .042
CT368a aroC Chorismate synthase 0.382 2.69 .042
CT004 gatB Aspartyl/glutamyl-tRNA amidotransferase subunit 0.327 2.87 .044
CT005 . . . Hypothetical protein 0.315 2.95 .046
CT218 surE 5’-nucleotidase SurE 0.291 3.47 .050
CT757 mraY Phospho-N-acetylmuramoyl-pentapeptide transferase 0.236 4.39 .051
CT319 rI11 50S ribosomal protein L11 0.273 3.03 .052
CT386 . . . Metal dependent hydrolase 0.273 3.42 .054
CT130a glnQ ABC amino acid transporter ATPase 0.455 2.38 .054
CT647 . . . Hypothetical protein 0.204 4.30 .056
CT017B . . . Hypothetical protein 0.236 4.44 .057
CT338 . . . Hypothetical protein 0.236 3.37 .059
CT002 gatC Glutamyl-tRNA amidotransferase subunit C 0.236 3.30 .060
CT351 . . . Hypothetical protein 0.273 3.32 .061
CT022 rI31 50S ribosomal protein L31 0.291 2.68 .065
CT133 . . . rRNA methylase 0.345 2.44 .068
CT687 . . . Cysteine desulfurase-like protein 0.236 4.00 .069
CT821 sucC Succinyl-CoA ligase subunit beta 0.236 3.18 .071
CT315 rpoB DNA-directed RNA polymerase subunit β 0.309 2.42 .072
CT144 . . . Hypothetical protein 0.255 3.12 .074
CT318 rI1 50S ribosomal protein L1 0.309 3.13 .075
CT104 Fabl Enoyl-acyl-carrier protein reductase 0.164 6.19 .080
CT128a Adk Adenylate kinase 0.382 2.23 .082
CT252C Lgt Prolipoprotein diacylglycerol transferase 0.273 2.68 .082
CT382 aroG Phospho-2-dehydro-3-deoxyheptonate aldolase 0.259 3.03 .084
CT717 . . . Type III secretion system ATP synthase 0.241 2.81 .086
CT808 cafE Rne/Rng family ribonuclease 0.145 5.61 .097
CT359 . . . Hypothetical protein 0.309 2.38 .098
CD8+ . . . . . . . . . . . . . . .
None . . . . . . . . . . . . . . .
Abbreviations: ID, identifier; OR, odds ratio.
a Expresses an immunodominant protein.
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protein, CT144, that we found to be protective when adminis-
tered as a vaccine in mice [34]was recognized with a greater fre-
quency by CD4+ T cells from follow-up–negative women
(P = .07). Tarp, which has been found to induce high titers of
antibodies in humans and protective immunity against upper
genital tract pathologies in mice [35], was investigated and
was more frequently recognized by CD8+ T cells from women
in the Cervix+ group, compared with those in the Endo+ group
(P = .11), although our small sample size likely limited our abil-
ity to detect statistically significant differences in these respons-
es. Because testing was limited to one third of the proteome, we
may have missed antigens important in protective immunity.
However, the current panel was based on prior human screens,
which allows for inclusion of proteins that might have been
omitted if the literature, animal studies, and predictive algo-
rithms were used as the determinants [21].
The proteins of recognized function associated with control
or resistance to infection in our cohort are involved in protein
synthesis, central metabolism, and type III secretion (Tables 1
and 2). This is consistent with our previous investigation,
using ATLAS [21]. Many of the antigens identified then as in-
ducing “effective” responses (ie, spontaneous clearance or lack
of infection despite confirmed exposure) were also genes in-
volved in central metabolism. Three proteins associated with ef-
fective immunity in that cohort (CT002, CT252, and CT757)
were also associated with resistance to infection in this cohort.
Additionally, CT564 and CT725, specifically associated with in-
fection control in our TRAC cohort, were associated with effec-
tive immunity previously [21]. In the prior study, CD8+ T-cell
responses were associated with effective immune responses in
men and women, which is consistent with a role for these
cells in prevention of ascension in this female only cohort.
These proteins are essential for intracellular survival of
C. trachomatis; since this pathogen lives within epithelial cells
and interacts intimately with the endoplasmic reticulum, pep-
tides of these essential proteins are likely shuttled through the
vesicular system and loaded into major histocompatibility com-
plex molecules. A limitation of the ATLAS screen is our inabil-
ity to confirm that each protein was successfully expressed and
presented by human APCs. Confirmation that a full-length pro-
tein is expressed in E. coli is derived from a cell-based assay in
which a B3Z T-cell hybridoma is tested for recognition of a C-
terminal SIINFEKL-tag inserted into each clone. The antigens
and tag are processed and presented to the T cells by murine
APCs [36]. However, we cannot be certain that the human
APCs presented each protein in comparable fashion.
Strengths of this study included comprehensive data on de-
mographic, clinical, and sexual characteristics, high rate of fol-
low-up, and a stringent requirement to complete 4 follow-up
visits over 1 year to be considered in the follow-up–negative
subgroup. A further strength is the nonbiased evaluation of
over one third of the chlamydial genome. Classifying upper
and lower genital tract infection at enrollment allowed us to
identify antigens important for control of infection. Additional-
ly, following these women longitudinally over 1 year allowed us
to identify antigens specifically associated with protection
against subsequent infection. Several of the proteins identified
were immunodominant, suggesting that this technology may
be capable of identifying novel vaccine candidates with the po-
tential for broad recognition by immunized individuals.
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